1. Home
  2. MRKR vs IZM Comparison

MRKR vs IZM Comparison

Compare MRKR & IZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • IZM
  • Stock Information
  • Founded
  • MRKR N/A
  • IZM 2011
  • Country
  • MRKR United States
  • IZM China
  • Employees
  • MRKR N/A
  • IZM N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • IZM Consumer Electronics/Video Chains
  • Sector
  • MRKR Health Care
  • IZM Consumer Discretionary
  • Exchange
  • MRKR Nasdaq
  • IZM Nasdaq
  • Market Cap
  • MRKR 21.9M
  • IZM 23.7M
  • IPO Year
  • MRKR N/A
  • IZM 2023
  • Fundamental
  • Price
  • MRKR $2.16
  • IZM $1.45
  • Analyst Decision
  • MRKR Strong Buy
  • IZM
  • Analyst Count
  • MRKR 1
  • IZM 0
  • Target Price
  • MRKR $19.00
  • IZM N/A
  • AVG Volume (30 Days)
  • MRKR 53.9K
  • IZM 70.5K
  • Earning Date
  • MRKR 11-14-2024
  • IZM 01-29-2025
  • Dividend Yield
  • MRKR N/A
  • IZM N/A
  • EPS Growth
  • MRKR N/A
  • IZM N/A
  • EPS
  • MRKR N/A
  • IZM N/A
  • Revenue
  • MRKR $5,395,849.00
  • IZM $177,933,890.00
  • Revenue This Year
  • MRKR $64.48
  • IZM N/A
  • Revenue Next Year
  • MRKR N/A
  • IZM N/A
  • P/E Ratio
  • MRKR N/A
  • IZM N/A
  • Revenue Growth
  • MRKR 79.04
  • IZM N/A
  • 52 Week Low
  • MRKR $1.83
  • IZM $1.43
  • 52 Week High
  • MRKR $5.99
  • IZM $52.21
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 32.84
  • IZM 20.28
  • Support Level
  • MRKR $1.83
  • IZM $1.44
  • Resistance Level
  • MRKR $2.79
  • IZM $1.56
  • Average True Range (ATR)
  • MRKR 0.28
  • IZM 0.08
  • MACD
  • MRKR -0.09
  • IZM -0.01
  • Stochastic Oscillator
  • MRKR 21.02
  • IZM 4.05

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About IZM ICZOOM Group Inc.

ICZOOM Group Inc is engaged in the sale of electronic component products to customers in China. These products are used by small and medium-sized enterprises (SMEs) in the consumer electronic industry, Internet of Things (IoT), automotive electronics, and industrial control segment. In addition to the sales of electronic component products, also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance and charges them additional service commission fees. The company earns maximum revenue from sale of electronic components.

Share on Social Networks: